Cost-effectiveness of HMG-COA reductase inhibition in primary prevention of CHD: New evidence comparing all available agents

被引：0
|
作者：
Huse, DM
Russell, MW
Miller, JD
Kraemer, DF
Hartz, SC
机构：
[1] MED RES INT,BURLINGTON,MA
[2] WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES,ANN ARBOR,MI 48105
来源：
AMERICAN JOURNAL OF MANAGED CARE | 1997年 / 3卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：LC21 / LC21
页数：1
相关论文
共 44 条
  • [21] Academic detailing to drive a new cost-effective therapy within the HMG-COA reductase inhibitor class
    Stahl, JS
    Torborg, SA
    Boreen, DM
    Burns, KD
    Waltermire, RD
    AMERICAN JOURNAL OF MANAGED CARE, 1997, 3 (10): : LC3 - LC3
  • [22] Inhibition of migration and proliferation of rat vascular smooth muscle cells by a new HMG-CoA reductase inhibitor, pitavastatin
    Kohno, M
    Shinomiya, K
    Abe, S
    Noma, T
    Kondo, I
    Oshita, A
    Takeuchi, H
    Takagi, Y
    Yukiiri, K
    Mizushige, K
    Ohmori, K
    HYPERTENSION RESEARCH, 2002, 25 (02) : 279 - 285
  • [23] Establishing the cost-effectiveness of statins in the primary prevention of CHD using a quasi Markov model
    Dewilde, S
    Davies, A
    Hutton, J
    VALUE IN HEALTH, 2003, 6 (06) : 664 - 665
  • [24] Secondary Prevention of Coronary Heart Disease in Elderly Patients Following Myocardial InfarctionAre All HMG-CoA Reductase Inhibitors Alike?
    Bijesh P. Maroo
    Carl J. Lavie
    Richard V. Milani
    Drugs & Aging, 2008, 25 : 649 - 664
  • [25] Secondary prevention of coronary heart disease in elderly patients following myocardial infarction - Are all HMG-CoA reductase inhibitors alike?
    Maroo, Bijesh P.
    Lavie, Carl J.
    Milani, Richard V.
    DRUGS & AGING, 2008, 25 (08) : 649 - 664
  • [26] Comparing Impact and Cost-Effectiveness of Primary Prevention Strategies for Lipid-Lowering
    Pletcher, Mark J.
    Lazar, Lawrence
    Bibbins-Domingo, Kirsten
    Moran, Andrew
    Rodondi, Nicolas
    Coxson, Pamela
    Lightwood, James
    Williams, Lawrence
    Goldman, Lee
    ANNALS OF INTERNAL MEDICINE, 2009, 150 (04) : 243 - U42
  • [27] A long-term comparative trial of cerivastatin sodium, a new HMG-CoA reductase inhibitor, in patients with primary hypercholesterolemia
    Sasaki, J
    Arakawa, K
    Yamamoto, K
    Kobori, S
    Ageta, M
    Kono, S
    CLINICAL THERAPEUTICS, 1998, 20 (03) : 539 - 548
  • [28] Cost-effectiveness analysis has to consider all available evidence when informing inputs
    Alvarez, Fabian P.
    Petitjean, Audrey
    Nealon, Joshua
    Hollingsworth, Rosalind
    Lopez-Belmonte, Juan Luis
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (03) : 694 - 695
  • [29] PREVENTION OF LDL-SUPPRESSION OF HMG-COA REDUCTASE (HMGR) ACTIVITY BY PROGESTERONE (PG) - EVIDENCE FOR CYTOCHROME-P-450 INVOLVEMENT
    SEXTON, RC
    GUPTA, A
    PANINI, SR
    RUDNEY, H
    FEDERATION PROCEEDINGS, 1987, 46 (06) : 2274 - 2274
  • [30] Preventing coronary heart disease in the managed care era: Improving the cost effectiveness of lipid-lowering therapy with HMG-CoA reductase inhibitors
    Jacobson, TA
    AMERICAN JOURNAL OF MANAGED CARE, 1997, 3 : S29 - S41
12345